<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[99, 105] response rate and the median survival<br>[109, 116] The overall response rate (CR+PR)<br>[136, 139] The median survival<br>[166, 168] Survival curve<br>[222, 226] disease-free life<br>[232, 234] Hematologic toxicities<br>[272, 277] immuno-enhancement activities.<br></td>
<td width=33%>
[99, 105] response rate and the median survival<br>[109, 116] The overall response rate (CR+PR)<br>[136, 139] The median survival<br>[166, 168] Survival curve<br>[222, 226] disease-free life<br>[232, 234] Hematologic toxicities<br>[272, 277] immuno-enhancement activities.<br></td>
<td width=33%>
[99, 105] response rate and the median survival<br>[110, 116] overall response rate (CR+PR)<br>[137, 139] median survival<br>[166, 174] Survival curve (Kaplan-meire's)<br>[222, 226] disease-free life<br>[232, 234] Hematologic toxicities<br>[272, 277] immuno-enhancement activities.<br>[291, 310] non-specific immunology activities and may be much useful for solid cancer patients as an adjuvant treatment.<br></td>
</tr>
